Nitroso/redox balance in myocardial infarction
Nitroso/redox balance in myocardial infarction
批准号:
8206727
负责人:
Joshua M Hare
金额:
$44.53万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-02-15 至 2013-12-31
关键词:
Adrenergic AgentsApoptosisAttentionBindingBiological AvailabilityBlood PlateletsCalciumCardiac MyocytesCardiovascular DiseasesCardiovascular systemCause of DeathCaveolaeCysteineDiseaseEnergy MetabolismEnzymesEquilibriumFunctional disorderGenerationsGrantHealthHeartHeart failureHomeostasisHumanIn VitroInjuryIschemiaKnock-outKnockout MiceLeft Ventricular FunctionLeft Ventricular RemodelingMediatingMethodsModelingMusMyocardialMyocardial InfarctionMyocardial IschemiaNOS1 geneNOS3 geneNitric OxideNitric Oxide SynthaseOrganellesOutcomeOxidasesOxidation-ReductionOxidative StressOxidoreductasePathway interactionsPatientsPhenotypePlayProductionProtein IsoformsProteinsPublishingReactive Oxygen SpeciesRegulationRelaxationReportingRoleS-NitrosoglutathioneSKIL geneSarcolemmaSarcoplasmic ReticulumSeriesSignal PathwaySignal TransductionSignaling MoleculeSiteSourceSulfhydryl CompoundsTestingVascular blood supplyWorkXanthine Oxidaseadrenergicbaseimprovedin vivoinhibitor/antagonistinsightnovelnovel therapeuticspublic health relevanceresearch study
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Nitric oxide (NO), a highly versatile signaling molecule, exerts a broad range of regulatory influences in the cardiovascular system that extend from endothelial relaxation to platelet function, myocardial contractility, Ca2+ cycling, and energy metabolism. Much attention has been paid to deciphering mechanisms for such diversity in signaling, but controversy still abounds. S-nitrosylation of cysteine thiols is a major signaling pathway through which NO exerts its actions. An emerging concept of NO pathophysiology is that the interplay between NO and reactive oxygen species (ROS), the nitroso/redox balance, is an important regulator of cardiovascular homeostasis. ROS readily react with NO and limit its bioavailability and also compete with NO for binding to the same sites in effector molecules. We and others have shown that specific NO synthase (NOS) isoforms reside in precise sub-cellular organelles in cardiac myocytes and interact with oxidative enzymes in a spatially confined matter. In this grant we propose experiments that will further elucidate the significance of nitroso/redox balance in health and disease. We will take advantage of 3 newly discovered phenomena, first that NOS1 translocates in myocardial infarction, second that S-nitrosylation is tightly regulated by S- nitrosoglutathione reductase (GSNOR), which decomposes SNO bonds and last, that the well-known cardioprotective effects of NO during myocardial ischemia are mediated at least in part by S-nitrosylation of Ca+2 handling proteins. The specific aims of this grant are to assess that 1.) NOS isoforms are in close contact with GSNOR and this close proximity allows for tight regulation of S-nitrosylation, 2.) After myocardial infarction (MI), there are selective, highly regulated interactions between xanthine oxidase and NOS1 (as opposed to NOS3) 3.) GSNOR plays a pivotal role in regulating S-nitrosylation in the heart after MI. Our work will provide an integrated view of the role of nitroso/redox balance in cardiovascular pathophysiology. The potential implications of our findings are highlighted by recent large-scale human studies where pharmacologic manipulation of oxidative and nitrosative pathways exerted salutary effects in patients with advanced heart failure.
PUBLIC HEALTH RELEVANCE: Myocardial infarction occurs when blood supply to the heart is inadequate and this represents the leading cause of death worldwide. In this Grant, we will explore the mechanisms through which the heart protects itself against injury. Our findings will have implications for developing new therapeutic strategies for myocardial infarction and other related common diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Full-scale GMP Production for a Pre-Clinical Systemic Delivered Mesenchymal Stem Cells Derived Extracellular Vesicles For Cardiovascular Disease
-
批准号:10721103
-
项目类别:
-
资助金额:$28.87万
-
财政年份:2023
-
负责人:Joshua M Hare
-
依托单位:
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial
-
批准号:10274833
-
项目类别:
-
资助金额:$117.83万
-
财政年份:2020
-
负责人:Joshua M Hare
-
依托单位:
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial
-
批准号:10295008
-
项目类别:
-
资助金额:$65.79万
-
财政年份:2020
-
负责人:Joshua M Hare
-
依托单位:
Production Assistance for Cellular Therapies (PACT)- Cell Processing Facilities Cell manufacturing and process development services for PCT0031-02: GMP Production of iPSC Line and Scale-up of Cardiac
-
批准号:10090766
-
项目类别:
-
资助金额:$101.72万
-
财政年份:2019
-
负责人:Joshua M Hare
-
依托单位:
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty
-
批准号:9922198
-
项目类别:
-
资助金额:$197.43万
-
财政年份:2018
-
负责人:Joshua M Hare
-
依托单位:
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome
-
批准号:9925908
-
项目类别:
-
资助金额:$46.55万
-
财政年份:2017
-
负责人:Joshua M Hare
-
依托单位:
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome
-
批准号:9348026
-
项目类别:
-
资助金额:$15.0万
-
财政年份:2017
-
负责人:Joshua M Hare
-
依托单位:
Nitric Oxide and sex differences in cardiac repair
-
批准号:9331951
-
项目类别:
-
资助金额:$40.61万
-
财政年份:2017
-
负责人:Joshua M Hare
-
依托单位:
Pathways to Cardiovascular Therapeutics
-
批准号:8986055
-
项目类别:
-
资助金额:$3.0万
-
财政年份:2015
-
负责人:Joshua M Hare
-
依托单位:
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy
-
批准号:8288406
-
项目类别:
-
资助金额:$71.55万
-
财政年份:2012
-
负责人:Joshua M Hare
-
依托单位:
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy
-
批准号:8448599
-
项目类别:
-
资助金额:$65.07万
-
财政年份:2012
-
负责人:Joshua M Hare
-
依托单位:
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy
-
批准号:8628873
-
项目类别:
-
资助金额:$66.46万
-
财政年份:2012
-
负责人:Joshua M Hare
-
依托单位:
Cardioprotective Effect of Growth Hormone Releasing Hormone
-
批准号:8065336
-
项目类别:
-
资助金额:$64.43万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Cardioprotective Effect of Growth Hormone Releasing Hormone
-
批准号:8208055
-
项目类别:
-
资助金额:$62.55万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8502552
-
项目类别:
-
资助金额:$62.02万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Cardioprotective Effect of Growth Hormone Releasing Hormone
-
批准号:8411600
-
项目类别:
-
资助金额:$64.93万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8300026
-
项目类别:
-
资助金额:$65.13万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8880266
-
项目类别:
-
资助金额:$60.41万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8205725
-
项目类别:
-
资助金额:$63.95万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Cardioprotective Effect of Growth Hormone Releasing Hormone
-
批准号:8589378
-
项目类别:
-
资助金额:$64.84万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: